Zentek to Present at the Sidoti & Company Virtual Small Cap Conference

Rhea-AI Summary

Zentek Ltd. (TSX-V:ZEN, OTC:ZENYF) announces that CEO Greg Fenton will present at the Sidoti & Company Virtual Small Cap Conference on January 20, 2022, at 9:15 AM ET. The presentation is accessible live here. Fenton will also participate in one-on-one meetings during the conference. Zentek is focused on developing healthcare solutions, notably ZENGuard™, a coating with 99% antimicrobial activity against COVID-19. The company has an exclusive deal for a rapid pathogen detection technology.

GUELPH, ON / ACCESSWIRE / January 17, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN) and (OTC:ZENYF), an IP development and commercialization company focused on next-gen healthcare solutions, announces that Chief Executive Officer Greg Fenton will present at the Sidoti & Company Virtual Small Cap Conference being held from January 19 - 20, 2022.

Mr. Fenton will deliver his corporate presentation on Thursday, January 20, 2022, at 9:15 AM ET, and can be accessed live:https://sidoti.zoom.us/webinar/register/WN_w9qcEwfQTym18vvLVVVyiQ

Mr. Fenton will also be available for one-on-one meetings throughout the conference. https://www.sidoti.com/events

About Zentek Ltd.

Zentek is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

For further information:

Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com

To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.com.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zentek Ltd.

View source version on accesswire.com:
https://www.accesswire.com/683694/Zentek-to-Present-at-the-Sidoti-Company-Virtual-Small-Cap-Conference

FAQ

When will Zentek's CEO present at the Sidoti Conference?

Zentek's CEO Greg Fenton will present on January 20, 2022, at 9:15 AM ET.

How can I access the live presentation by Zentek's CEO?

The live presentation can be accessed here.

What is ZENGuard™ developed by Zentek?

ZENGuard™ is a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19.

What is the focus of Zentek Ltd.?

Zentek is focused on developing next-gen healthcare solutions in prevention, detection, and treatment.

What technology is Zentek commercializing?

Zentek has an exclusive agreement for a new rapid pathogen detection technology.

Where can I find more information about Zentek?

More information can be found on Zentek's website at www.Zentek.com.